Effects of hyaluronic acid on osteopontin mRNA and CD44 mRNA expression in human osteoarthritic chondrocytes

doi:10.3969/j.issn.2095-4344.2014.38.018

Abstract

Abstract:

BACKGROUND: Progressive fracture of the cartilage is considered the characteristic lesion in later osteoarthritis, the expression of osteoarthritis-related factors such as hyaluronic acid, osteopontin and CD44 in osteoarthritic cartilage is increased.
OBJECTIVE: To investigate the effect of hyaluronic acid on the expression of osteopontin mRNA and CD44 mRNA of chondrocytes in the in vitro cultured chondrocytes of patients with knee osteoarthritis.
METHODS: The cartilage samples obtained from osteoarthritic patients were cultured and purified into acquire chondrocytes in vitro, and the cells were divided into three groups: blank control group, hyaluronic acid (100 mg/mL) group and hyaluronidase (200 mg/mL) group. After 48 hours of cell culture, real-time quantitative polymerase chain reaction assay was used to detect the expression of CD44 mRNA and osteopontin mRNA. The difference of the expression levels before and after the intervention of hyaluronic acid was compared and analyzed using SPSS 17.0 software.
RESULTS AND CONCLUSION: Compared with the blank control group, hyaluronic acid (100 mg/mL) upregulated osteopontin mRNA expression in the chondrocytes, hyaluronidase (200 mg/mL) also reduced osteopontin mRNA expression in the chondrocytes. The CD44 mRNA expression in the chondrocytes of
hyaluronic acid (100 mg/mL) group and hyaluronidase (200 mg/mL) group was lower than that in the blank control group. Hyaluronic acid can upregulate the expression of the osteopontin mRNA expression in the osteoarthritic chondrocytes; the biphasic effects of hyaluronic acid on CD44 mRNA expression in osteoarthritic chondrocytes might be associated with the molecule weight of hyaluronic acid.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

全文链接：

Key words: osteoarthritis, knee, chondrocytes, osteopontin, hyaluronic acid, antigen, CD44

CLC Number:

R318

Zhou Bin, Zhang Fang-jie, Luo Wei, Gao Shu-guang, Zeng Chao, Xiong Yi-lin, Li Yu-sheng,. Effects of hyaluronic acid on osteopontin mRNA and CD44 mRNA expression in human osteoarthritic chondrocytes[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(38): 6172-6178.

Figures/Tables 2

References

[1] Pullig O,Pfander D,Swoboda B.[Molecular principles of induction and progression of arthrosis]. Orthopade. 2001; 30(11):825-833.
[2] Chen C, Tambe D T, Deng L, et al. Biomechanical properties and mechanobiology of the articular chondrocyte. Am J Physiol Cell Physiol.2013;305(12):C1202-C1208.
[3] Laurent TC, Fraser JR. Hyaluronan. FASEB J.1992;6(7): 2397-2404.
[4] Felson DT, Lawrence RC, Dieppe PA, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med. 2000;133(8):635-646.
[5] Fraser JR, Laurent TC, Laurent UB. Hyaluronan: its nature, distribution, functions and turnover. J Intern Med.1997;242(1): 27-33.
[6] Wells A F, Klareskog L, Lindblad S, et al.Correlation between increased hyaluronan localized in arthritic synovium and the presence of proliferating cells. A role for macrophage-derived factors. Arthritis Rheum.1992;35(4):391-396.
[7] Denhardt DT,Noda M.Osteopontin expression and function: role in bone remodeling. J Cell Biochem Suppl.1998;30-31: 92-102.
[8] Gravallese EM. Osteopontin: a bridge between bone and the immune system. J Clin Invest.2003;112(2):147-149.
[9] Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol Suppl. 1993;39:3-9.
[10] Dahl LB, Dahl IM, Engstrom-Laurent A, et al. Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Ann Rheum Dis.1985;44(12):817-822.
[11] Burdo TH, Wood MR, Fox HS. Osteopontin prevents monocyte recirculation and apoptosis. J Leukoc Biol. 2007; 81(6):1504-1511.
[12] Lin YH, Yang-Yen HF. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway.J Biol Chem.2001;276(49):46024-46030.
[13] Screaton GR, Bell MV, Jackson DG, et al. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci U S A.1992;89(24):12160-12164.
[14] Naor D, Wallach-Dayan SB, Zahalka MA, et al. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol.2008;18(4):260-267.
[15] Bajorath J. Molecular organization, structural features, and ligand binding characteristics of CD44, a highly variable cell surface glycoprotein with multiple functions. Proteins. 2000; 39(2):103-111.
[16] Salter DM, Godolphin JL, Gourlay MS, et al.Analysis of human articular chondrocyte CD44 isoform expression and function in health and disease.J Pathol.1996;179(4):396-402.
[17] Zhang FJ, Luo W, Gao SG, et al. Expression of CD44 in articular cartilage is associated with disease severity in knee osteoarthritis.Mod Rheumatol.2013;23(6):1186-1191.
[18] Martinez-Sanz E, Ossipov DA, Hilborn J, et al. Bone reservoir: Injectable hyaluronic acid hydrogel for minimal invasive bone augmentation.J Control Release.2011;152(2):232-240.
[19] Mendes RM, Silva GA, Lima MF, et al. Sodium hyaluronate accelerates the healing process in tooth sockets of rats. Arch Oral Biol.2008;53(12):1155-1162.
[20] Kim J, Kim IS, Cho TH, et al. In vivo evaluation of MMP sensitive high-molecular weight HA-based hydrogels for bone tissue engineering.J Biomed Mater Res A. 2010;95(3): 673-681.
[21] Xu C, Wang Y, Yu X, et al. Evaluation of human mesenchymal stem cells response to biomimetic bioglass-collagen- hyaluronic acid-phosphatidylserine composite scaffolds for bone tissue engineering. J Biomed Mater Res A. 2009;88(1): 264-273.
[22] Gao C, Guo H, Downey L, et al. Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells. Carcinogenesis.2003;24(12):1871-1878.
[23] Zhang FJ, Gao SG, Cheng L, et al. The effect of hyaluronic acid on osteopontin and CD44 mRNA of fibroblast-like synoviocytes in patients with osteoarthritis of the knee. Rheumatol Int.2013;33(1):79-83.
[24] Chow G, Nietfeld JJ, Knudson CB, et al. Antisense inhibition of chondrocyte CD44 expression leading to cartilage chondrolysis.Arthritis Rheum.1998;41(8):1411-1419.
[25] Kim MS, Park MJ, Moon EJ, et al. Hyaluronic acid induces osteopontin via the phosphatidylinositol 3-kinase/Akt pathway to enhance the motility of human glioma cells. Cancer Res. 2005;65(3):686-691.
[26] Brun P,Zavan B,Vindigni V,et al.In vitro response of osteoarthritic chondrocytes and fibroblast-like synoviocytes to a 500-730 kDa hyaluronan amide derivative. J Biomed Mater Res B Appl Biomater.2012;100(8):2073-2081.
[27] Julovi SM,Ito H,Nishitani K,et al.Hyaluronan inhibits matrix metalloproteinase-13 in human arthritic chondrocytes via CD44 and P38. J Orthop Res.2011;29(2):258-264.
[28] Hiraoka N, Takahashi KA, Arai Y, et al. Intra-articular injection of hyaluronan restores the aberrant expression of matrix metalloproteinase-13 in osteoarthritic subchondral bone. J Orthop Res.2011;29(3):354-360.
[29] Yasuda T. Comparison of hyaluronan effects among normal, osteoarthritis, and rheumatoid arthritis cartilages stimulated with fibronectin fragment.Biomed Res.2010;31(1):63-69.
[30] Yatabe T, Mochizuki S, Takizawa M, et al. Hyaluronan inhibits expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic chondrocytes. Ann Rheum Dis, 2009,68(6): 1051-1058.
[31] Dunn S, Kolomytkin OV, Waddell DD, et al. Hyaluronan- binding receptors: possible involvement in osteoarthritis. Mod Rheumatol.2009;19(2):151-155.
[32] Smith MM, Cake MA, Ghosh P, et al.Significant synovial pathology in a meniscectomy model of osteoarthritis: modification by intra-articular hyaluronan therapy. Rheumatology (Oxford).2008;47(8):1172-1178.
[33] Wang CT, Lin YT, Chiang BL, et al.High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis. Osteoarthritis Cartilage.2006;14(12): 1237-1247.
[34] Attur MG, Dave MN, Stuchin S, et al.Osteopontin: an intrinsic inhibitor of inflammation in cartilage. Arthritis Rheum. 2001; 44(3):578-584.
[35] Matsui Y, Iwasaki N, Kon S, et al. Accelerated development of aging-associated and instability-induced osteoarthritis in osteopontin-deficient mice. Arthritis Rheum.2009;60(8): 2362-2371.
[36] Little CB, Barai A, Burkhardt D, et al. Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development. Arthritis Rheum.2009;60(12):3723-3733.
[37] Glasson SS, Askew R, Sheppard B, et al.Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature.2005;434(7033):644-648.
[38] Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science.2000;287(5454):860-864.
[39] O'Regan AW, Nau GJ, Chupp GL, et al. Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks. Immunol Today.2000;21(10):475-478.
[40] Smith MM, Russell AK, Schiavinato A, et al. A hexadecylamide-derivative of hyaluronan (HYMOVIS(R)) has superior beneficial effects on human osteoarthritic chondrocytes and synoviocytes than unmodified hyaluronan.J Inflamm (Lond).2013;10(1):26.